Insurers cut back GLP-1 coverage as demand soars: Found study
4.8 (283) · $ 23.50 · In stock
As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.
Ozempic vs. Metformin: Which Is Right for You?
Ozempic, Wegovy and other drugs: Who are they for?
I miss eating': the truth behind the weight loss drug that makes food repulsive, Food
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type
Viewpoints Eaton Vance
20% of Americans Would Change Jobs to Gain Ozempic, Wegovy Coverage
20% of Americans Would Change Jobs to Gain Ozempic, Wegovy Coverage
Glucagon-Like Peptide 1 (GLP-1) Agonists Market to Reach USD 20.15 Billion During Forecast Period - Digital Journal
Stock market today: Live updates
Shortage of GLP-1 receptor agonists says DHSC - The Diabetes Times
Consensus Recommendations on GLP-1 RA Use in the Management of
As the market for new weight loss drugs soars, people with diabetes pay the price
If I'm Out of Insulin, I'm Going to Die”: United States' Lack of Regulation Fuels Crisis of Unaffordable Insulin
